2026-09-09T07:03:31Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/119242026-07-18T00:05:28Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Zubiaur, Pablo Saiz Rodríguez, Miriam Abad‐Santos, Francisco 2026-07-17T11:26:53Z 2026-07-17T11:26:53Z 2023-01 0753-3322 https://hdl.handle.net/10259/11924 10.1016/j.biopha.2022.114003 On August 12, 2022, Biomedicine and Pharmacotherpy published a systematic review on the pharmacogenetics of siponimod by Díaz-Villamarín et al. [1] We would like to acknowledge the work done by the authors, as siponimod is a drug that may occupy a priority place in the management of secondarily progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. Therefore, we believe that research aimed at clarifying the impact of genetic variants on the effectiveness and safety of this drug is needed; therefore, we applaud the authors’ efforts with this systematic review. We consider that there are several inconsistencies in the therapeutic recommendations contained in the siponimod drug label and in those issued by the two most relevant international associations in pharmacogenetics: the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). P. Zubiaur is financed by Universidad Autónoma de Madrid, Margarita Salas contract, grants for the requalification of the Spanish university system. eng Elsevier Biomedicine & Pharmacotherapy. 2023, V. 157, art. 114003 https://doi.org/10.1016/j.biopha.2022.114003 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Pharmacogenetics Siponimod Secondarily progressive multiple sclerosis (SPMS) Farmacogenómica Esclerosis múltiple Pharmacogenomics Multiple sclerosis “Pharmacogenetics of siponimod: A systematic review” by Díaz-Villamarín et al. – Information is power info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Biomedicine & Pharmacotherapy 157